Cepheid Now Covered by Analysts at SunTrust (CPHD)
Analysts at SunTrust initiated coverage on shares of Cepheid (NASDAQ:CPHD) in a research report issued to clients and investors on Thursday, AnalystRatings.Net reports. The firm set a “neutral” rating on the stock.
Cepheid (NASDAQ:CPHD) traded up 2.84% during mid-day trading on Thursday, hitting $37.70. The stock had a trading volume of 532,912 shares. Cepheid has a one year low of $28.12 and a one year high of $40.31. The stock’s 50-day moving average is $37.80 and its 200-day moving average is $36.56. The company’s market cap is $2.543 billion.
Cepheid (NASDAQ:CPHD) last announced its earnings results on Thursday, July 18th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.02. The company had revenue of $96.00 million for the quarter, compared to the consensus estimate of $92.57 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. The company’s quarterly revenue was up 18.5% on a year-over-year basis. Analysts expect that Cepheid will post $-0.26 EPS for the current fiscal year.
A number of other firms have also recently commented on CPHD. Analysts at Wedbush raised their price target on shares of Cepheid from $37.00 to $42.00 in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Separately, analysts at Merrill Lynch downgraded shares of Cepheid from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. Finally, analysts at Bank of America Corp. downgraded shares of Cepheid from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, October 1st. They now have a $41.00 price target on the stock, up previously from $39.00. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company. Cepheid presently has a consensus rating of “Hold” and a consensus target price of $40.53.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.